364 related articles for article (PubMed ID: 31085701)
21. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1.
Rosner M; Hengstschläger M
Hum Mol Genet; 2008 Oct; 17(19):2934-48. PubMed ID: 18614546
[TBL] [Abstract][Full Text] [Related]
22. Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma.
Yu XN; Zhang GC; Sun JL; Zhu HR; Shi X; Song GQ; Weng SQ; Dong L; Liu TT; Shen XZ; Guo HY; Zhu JM
Ann Surg Oncol; 2020 May; 27(5):1546-1557. PubMed ID: 32157528
[TBL] [Abstract][Full Text] [Related]
23. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
Beauchamp EM; Abedin SM; Radecki SG; Fischietti M; Arslan AD; Blyth GT; Yang A; Lantz C; Nelson A; Goo YA; Akpan I; Eklund EA; Frankfurt O; Fish EN; Thomas PM; Altman JK; Platanias LC
Blood; 2019 Mar; 133(11):1171-1185. PubMed ID: 30587525
[TBL] [Abstract][Full Text] [Related]
24. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.
Liu P; Gan W; Inuzuka H; Lazorchak AS; Gao D; Arojo O; Liu D; Wan L; Zhai B; Yu Y; Yuan M; Kim BM; Shaik S; Menon S; Gygi SP; Lee TH; Asara JM; Manning BD; Blenis J; Su B; Wei W
Nat Cell Biol; 2013 Nov; 15(11):1340-50. PubMed ID: 24161930
[TBL] [Abstract][Full Text] [Related]
25. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
Wang Y; Mikhailova M; Bose S; Pan CX; deVere White RW; Ghosh PM
Oncogene; 2008 Nov; 27(56):7106-17. PubMed ID: 18776922
[TBL] [Abstract][Full Text] [Related]
26. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract][Full Text] [Related]
27. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition.
Matsubara S; Tsukasa K; Kuwahata T; Takao S
Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605
[TBL] [Abstract][Full Text] [Related]
28. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
29. STAT3-mediated MLST8 gene expression regulates cap-dependent translation in cancer cells.
Lee H; Chin H; Kim H; Jung H; Lee D
Mol Oncol; 2020 Aug; 14(8):1850-1867. PubMed ID: 32495998
[TBL] [Abstract][Full Text] [Related]
30. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
31. Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.
Wang S; Amato KR; Song W; Youngblood V; Lee K; Boothby M; Brantley-Sieders DM; Chen J
Mol Cell Biol; 2015 Apr; 35(7):1299-313. PubMed ID: 25582201
[TBL] [Abstract][Full Text] [Related]
32. MITF-MIR211 axis is a novel autophagy amplifier system during cellular stress.
Ozturk DG; Kocak M; Akcay A; Kinoglu K; Kara E; Buyuk Y; Kazan H; Gozuacik D
Autophagy; 2019 Mar; 15(3):375-390. PubMed ID: 30290719
[TBL] [Abstract][Full Text] [Related]
33. Liraglutide Improves Endothelial Function via the mTOR Signaling Pathway.
Wu H; Xiao C; Zhao Y; Yin H; Yu M
J Diabetes Res; 2021; 2021():2936667. PubMed ID: 34447854
[TBL] [Abstract][Full Text] [Related]
34. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
35. Functional Impacts of the BRCA1-mTORC2 Interaction in Breast Cancer.
Krieger KL; Hu WF; Ripperger T; Woods NT
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771139
[TBL] [Abstract][Full Text] [Related]
36. Cryo-EM structure of human mTOR complex 2.
Chen X; Liu M; Tian Y; Li J; Qi Y; Zhao D; Wu Z; Huang M; Wong CCL; Wang HW; Wang J; Yang H; Xu Y
Cell Res; 2018 May; 28(5):518-528. PubMed ID: 29567957
[TBL] [Abstract][Full Text] [Related]
37. TIS21
Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
[TBL] [Abstract][Full Text] [Related]
38. Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc.
Li M; Lazorchak AS; Ouyang X; Zhang H; Liu H; Arojo OA; Yan L; Jin J; Han Y; Qu G; Fu Y; Xu X; Liu X; Zhang W; Yang Z; Ruan C; Wang Q; Liu D; Huang C; Lu L; Jiang S; Li F; Su B
Cell Mol Immunol; 2019 Sep; 16(9):757-769. PubMed ID: 30705387
[TBL] [Abstract][Full Text] [Related]
39. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
40. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
